A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population

Bulletin of the National Research Centre - Tập 45 Số 1 - 2021
Chinonyerem O. Iheanacho1, Uchenna I. H. Eze2, Emmanuel A. Adida1
1Department of Clinical Pharmacy and Public Health, Faculty of Pharmacy, University of Calabar, Calabar, PMB 1115, Nigeria
2Department of Clinical Pharmacy and Biopharmarcy, Faculty of Pharmacy, Olabisi Onabanjo University, Sagamu, Nigeria

Tóm tắt

Abstract Background High effectiveness of COVID-19 vaccines is essential for the pandemic control. This study systematically reviewed available evidence on effectiveness of ChAdOx1 and BNT162b2 vaccines in the general population, for improved vaccine policies and strategies. Main body of the abstract Using several keywords, a search of Scopus, PubMed, Google scholar and Hinari databases was conducted from December 1, 2020 to June 9, 2021. Eligible studies comprising original studies reporting effectiveness of the vaccines, were included following PRISMA guidelines. Individual studies were assessed for quality using National Heart, Lung and Blood Institute quality assessment tool. A total of 1766 titles were retrieved and 11 were included, out of which only 5 were peer-reviewed. Although data availability was limited, studies suggest equivalent effectiveness of BNT162b2 and ChAdOx1 COVID-19 vaccine against SARS-CoV-2 infection and COVID-19 related morbidity and mortality. Vaccine effectiveness increased steadily to about 35 days, with an enhanced effectiveness following the second dose. Short conclusion BNT162 and ChAdOx1 vaccines were associated with equivalent and high effectiveness which increased with time and a second dose in the general population. This encourages continued practice of other preventive measures, particularly during the first week of vaccination, and reinforces the need for a second dose.

Từ khóa


Tài liệu tham khảo

Amit S, Beni SA, Biber A, Grinberg A, Lashem E, Regev-Yochay G (2021a) Post vaccination COVID-19 among healthcare workers, Israel. Emerg Infect Dis. https://doi.org/10.3201/eid2704.210016

Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E (2021b) Early rate reduction of SARSCoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. https://doi.org/10.1011/S0140-6736(21)00448-7

Bernal JL, Andrew N, Gower C, Stowe J, Robertson C, Tessier E, Simmons R, Cottrell S, Roberts R, O’Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M (2021a) Early effectiveness of Covid-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalization and mortality in older adults in England. MedRxiv. https://doi.org/10.1101/2021.03.01.21252652

Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall SJ et al (2021b) Effectiveness of COVID-19 vaccines against B.1.617.2 variant. MedRxiv. https://doi.org/10.1101/2021.5.22.21.257658

Bernal JL, Andrews N, Gower C, Stower J, Tessier E, Simmons R, Ramsay M (2021c) Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19. MedRxiv. https://doi.org/10.1101/2021.05.14.21257218

Chodlick G, Tene L, Patalon T, Gazit S, Tov AB, Cohen D, Muhsen K (2021) The effectiveness of the first dose of BNT162b2 vaccine at reducing SARS.CoV-2 infection 13–24 days after immunization: real world evidence. MedRxiv. https://doi.org/10.1101/2021.01.27.21250612

Cooper DM, Afghani B, Byington CL, Cunningham CK, Golub S, Lu KD, Radom-Aizik S, Ross LF, Singh J, Smoyer WE, Lucas CT, Tunney J, Zaldivar F, Ulloa ER (2021) SARS-CoV-2 vaccine testing and trials in the paediatric population: biologic, ethical, research, and implementation challenges. Pediatric Res. https://doi.org/10.1038/s41390-021-01402-z

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Kartz MA, Hernan MA, Lipsitch M, Reis B, Balicer RD (2021) BNT162b2 mRNA Covid-119 vaccine in a nationwide mass vaccination setting. N Engl J Med. https://doi.org/10.1056/NEJMoa2101765

Department of health and social care. Statement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines. https://www.gov.uk/government/news/statement-from-the-uk-chief-medical-officers-on-the-prioritisation-of-first-doses-of-covid-19-vaccines.

Forni G, Mantovani A (2021) On behalf of COVID-19 commision of Academia Nazionale dei Lincei, Rome. Cell Death Differ 28:626–639. https://doi.org/10.1038/s41418-020-00720-9

Haas EJ, Angulo F, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jorder L, Levy Y, Alry-Preis S (2021) Impact and effectiveness of mRNA, BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397(10287):1819–1829. https://doi.org/10.1016/S0140-6736(21)00947-8

Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A et al (2021) COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The Lancet 397(10286):1725–1735. https://doi.org/10.1016//S0140-6736(21)00790-X

Helfand BKI et al (2020) The exclusion of older persons from vaccine and treatment trials for COVID-19. J Am Med Assoc 180(11):1546–1549

Helms-Mousten IR, Emborg H, Nielsen J, Neilsen KF, Krause TG, Molbak K, Moller KL, Berthelsen AN, Valentiner-Branth P (2021) Vaccine effectiveness after first and second dose of the BNT162b2 mRNA COVID-19 vaccine in longterm care facility residents and healthcare workers: a Danish cohort study. MedRxiv. https://doi.org/10.1101/2021.03.08.21252200

Hunter PR, Brainard J (2021) Estimating effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose (2021) A reanalysis of a study of “real world” vaccination outcomes from Israel. MedRxiv. https://doi.org/10.1101/2021.02.01.21250957

McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ (2021) Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vac 6:74. https://doi.org/10.1038/s41541-021-00336-1

Moher D et al (2009) Preferred reporting items for systematic reviews and meta-analysis: The PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed1000097

National Heart, Lung, and Blood Institute. Study Quality Assessment Tools. https://www.nhlbi.nih.gov/. Accessed May 31, 2021.

Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, Agha M, Agha R (2020) The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg 78:185–193. https://doi.org/10.1016/j.ijsu.2020.04.018

Polack FP, Thomas SJ, Kitchen N, Absalon J, Gurtman A, Lockhart S, Perez JL et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383:2603–2615. https://doi.org/10.1056/NEJMoa2034577

Pritchard E et al (2021) Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. https://doi.org/10.1038/s41591-021-01410-w

Raj N, Fernandes S, Charyulu NR, Dubey A, Ravi GS, Hebbar S (2019) Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. Ther Adv Drug Saf. https://doi.org/10.1177/2042098619865413

Sanyaolu A, Okorie C, Hossein Z, Patidar R, Desai P, Prakash S, Jaferi U, Mangat J, Marinkovic A (2020) Global pandemicity of COVID-19: situation report as of June 9, 2020. Infect Dis Res Treat. https://doi.org/10.1177/1178633721991260

Sheikh A, McMenamin J, Taylor RC (2021) SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admissions, and vaccine effectiveness. Lancet. https://doi.org/10.1016/S0140-6736(21)01358-1

Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, Fuller C, Irwin-Singer A, Davies D, Tut G, Bernal JL, Moss P, Hayward A, Copas A, Shallcross L (2021) Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities (VIVALDI study). MedRxiv. https://doi.org/10.1101/2021.03.26.21254391

Vasileious E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradly D, Chuter A, de Lusignan S, Marple J, McCowan C, McGagh D, McMenamin J, Moore E, Murray JL, Pan J, Ritchie L, Shah SA, Stock S, Torabi F, Tsang RS, Wood R, Woolhouse M, Robertson C, Sheikh A (2021) Interim findings from first dose mass COVID-19 vaccination roll-out and COVID-19 hospital admission in Scotland: a national prospective cohort study. Lancet 397(10285):1646–1657. https://doi.org/10.1016/s0140-6734(21)00677-2

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111

Welch MJ, Lally R, Miller JE, Pittman S, Brodsky L, Caplan AL, Uhlenbrauck G, Louzao DM, Fischer JH, Wilfond B (2015) The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials. Clin Trials 12(5):503–510. https://doi.org/10.1177/174074515597701

World Health Oganisation (WHO) WHO issues its first emergency validation for a COVID-19 vaccine and emphasizes need for equitable global service. https://www.who.int/home/news/. Accessed June 19, 2021a.

World Health Organisation. https://covid-19.who.int/info. Accessed 19 June 19 2021b.

Thông tin
Thông tin xuất bản

Bulletin of the National Research Centre

Tập 45 Số 1

Thông tin tác giả